Events

2018 News Releases



Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle  
06/26/18Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif., June 26, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects. Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.  Preclinical studies show that R835 inhibits both the IRAK1 and IRAK4 signaling pathwa... 
 Printer Friendly Version
06/20/18Rigel Announces Poster Presentations at FOCIS Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting in San Francisco, June 20-23, 2018.  Poster presentation details: Thursday, June 21st, 6:25–7:30pm PDT Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor, in Adult Persistent/Chronic Immune Thr... 
 Printer Friendly Version
06/12/18Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
SOUTH SAN FRANCISCO, Calif., June 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at the 23rd Congress of the European Hematology Association (EHA) being held June 14-17, 2018, in Stockholm, Sweden.  Presentation Details: Title: FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF ... 
 Printer Friendly Version
05/31/18Rigel to Present at Jefferies 2018 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018 at 10:30am EDT.  To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minute... 
 Printer Friendly Version
05/30/18Rigel Appoints Dean Schorno as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., May 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO). Formerly the CFO and Head of Operations at 23andMe, Inc., Mr. Schorno brings to Rigel over fifteen years of experience leading finance functions at innovative commercial-stage biotechnology companies. "Dean joins the Rigel management team at an important crossroad as we transi... 
 Printer Friendly Version
05/29/18Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
Launches RIGEL ONECARE™ to Support Patients and Providers SOUTH SAN FRANCISCO, Calif., May 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE, an oral spleen tyrosine kinase (SYK) inhibitor tha... 
 Printer Friendly Version
05/01/18Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
Rigel Expected to Launch TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the first quarter ended March 31, 2018. TAVALISSE Launch Update During the conference call today, Rigel will discuss the TAVALISSE market access plans, including the wholesale acquisition cost ... 
 Printer Friendly Version
04/30/18TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
SOUTH SAN FRANCISCO, Calif., April 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the American Journal of Hematology has published positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of adults with chronic immune thrombocytopenia (ITP). The study, "Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two P... 
 Printer Friendly Version
04/24/18Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by dialing 855-892-1489... 
 Printer Friendly Version
04/19/18Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the public.  The gross proceeds to Rigel from this offering are expected to be $62.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Rigel.  All of the shares in t... 
 Printer Friendly Version
04/18/18Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assuranc... 
 Printer Friendly Version
04/17/18Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
TAVALISSE Offers First-in-Class Treatment with Unique Mechanism of Action U.S. Commercial Launch Expected in Late May 2018 Conference Call and Webcast to be Held Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immun... 
 Printer Friendly Version
04/12/18Rigel Makes Statement Regarding Website Error
SOUTH SAN FRANCISCO, Calif., April 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the U.S. Food and Drug Administration's (FDA) review of the New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP).  The website has been corrected.  The FDA is continuing its review of the NDA a... 
 Printer Friendly Version
04/03/18Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
Company to host a conference call today at 8:00AM EDT to Discuss the Study Results SOUTH SAN FRANCISCO, Calif., April 3, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced topline data from its proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy (IgAN), an orphan autoimmune disease of the kidneys. The trial did not achieve statistical significance for its primary endpoint, which was mean change in proteinuria comparing fostamatinib do... 
 Printer Friendly Version
03/06/18Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., March 6, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year end 2017. Recent Achievements The U.S. Food and Drug Administration (FDA) is continuing its review of Rigel's New Drug Application (NDA) for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Prescription Drug User F... 
 Printer Friendly Version
03/01/18Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
SOUTH SAN FRANCISCO, Calif., March 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phase 2 clinical study in patients with warm antibody autoimmune hemolytic anemia (AIHA) will be presented at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America on March 8 – 10, 2018 in San... 
 Printer Friendly Version
02/27/18Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2017 financial results after market close on Tuesday, March 6, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by diali... 
 Printer Friendly Version
01/04/18Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 10, 2018, at 1:30pm PST (see webcast details below). Rigel's presentation will include a review of the company's New Drug Application... 
 Printer Friendly Version